Announcements Trials
Browse Landscape

Status

Available 3No longer available 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 1078Observational 134Expanded_access 4

Sponsor

Cancer Type

Thoracic 8Sarcoma 7Genitourinary 5Gastrointestinal 5CNS 5Other hematologic neoplasm 4Lymphoid 4Breast 4Tumor-Agnostic 2Myeloid 2Gynecologic 2Dermatologic 2Plasma cell 1Head & Neck 1Endocrine 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Mastocytosis, Systemic 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Leukemia, Mast-Cell 1Leukemia 1Granuloma, Plasma Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

tisagenlecleucel 1ceritinib 1brexucabtagene autoleucel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Expanded_access × Lymphoid × 90 days × Clear all
NCT06915766 2026-05-08

Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis

Cogent Biosciences, Inc.

Available
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT03601442 2026-04-23

Managed Access Programs for CTL019, Tisagenlecleucel

Novartis

Available
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

NCT05776134 2026-04-08

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

Gilead Sciences

Available
LymphoidOther hematologic neoplasm

Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05100134 2026-04-01

Managed Access Programs for LDK378, Ceritinib

Novartis

No longer available
LymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡